Cytotoxic chemotherapy for metastatic renal cell carcinoma

Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163:408–417 Kish JA, Wolf M, Crawford ED, et al (1994) Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer 74:916–919 Mertens WC, Eisenhauer EA, Moore M, et al (1993) Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 4:331–332 Weissbach L, de Mulder P, Osieka R, et al (1992) Phase II study of gemcitabine in renal cancer. Proc Am Soc Clin Oncol 11:219 Townsley CA, Chi K, Ernst DS, et al (2003) Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 21:1524–1529 Rini BI, Vogelzang NJ, Dumas MC, Wade JL, 3rd, Taber DA, Stadler WM (2000) Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18:2419–2426 Ryan CW, Vogelzang NJ, Stadler WM (2002) A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer 94:2602–2609 Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM (2002) A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 95:1629–1636 George CM, Vogelzang NJ, Rini BI, Geoffroy FJ, Kollipara P, Stadler WM (2002) A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol 13:116–120 Stadler WM, Huo D, George C, et al (2003) Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 170:1141–1145